Figure 4
PGV-1 suppresses the growth of pre-formed tumors in CDX-M. (a) Experimental design to test the anti-tumor effects of PGV-1 on pre-formed tumors in CDX-M. (b,c) MIA PaCa-2 cells (1 × 107 cells) were subcutaneously injected into nude mice. When tumors reached a size of 5 × 5 × 5 mm3, mice were randomly grouped into 4 groups and treated differently: ①control (PBS, per os), ② orally administered (p.o.) PGV-1 (25 mg/kg BW) in corn oil every 2 days, ③ intraperitoneally (i.p.) administered gemcitabine (100 mg/kg) in normal saline twice a week, and ④ the combination of PGV-1 (every two days, 25 mg/kg BW, p.o.) and gemcitabine (twice a week, 100 mg/kg BW, i.p.). Tumor volumes were measured every 2 days (b), and mice were sacrificed on day 20. Tumor volumes on days 6 and 20 were compared (c). P values were calculated with Student’s t test. Data are the average of 4 independent experiments shown as mean ± SEM (one to four mice were used for each independent experiment).
